0.1M Tris, 0.1M Glycine, 10% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1mg/ml(Please refer to the vial label for the specific concentration.)
Recombinant protein encompassing a sequence within the N-terminus region of human PLCG2. The exact sequence is proprietary.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
PLCG2 antibody, phospholipase C-IV antibody, phospholipase C gamma 2 antibody, phospholipase C, gamma 2 (phosphatidylyinositol-specific) antibody, phospholipase C-gamma-2 antibody, phosphoinositide phospholipase C-gamma-2 antibody, PLC-IV antibody, PLC-gamma-2 antibody, 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-2 antibody, phospholipase C, gamma 2 (phosphatidylinositol-specific) antibody
Enzymes of the phospholipase C family catalyze the hydrolysis of phospholipids to yield diacylglycerols and water-soluble phosphorylated derivatives of the lipid head groups. A number of these enzymes have specificity for phosphoinositides. Of the phosphoinositide-specific phospholipase C enzymes, C-beta is regulated by heterotrimeric G protein-coupled receptors, while the closely related C-gamma-1 (PLCG1; MIM 172420) and C-gamma-2 enzymes are controlled by receptor tyrosine kinases. The C-gamma-1 and C-gamma-2 enzymes are composed of phospholipase domains that flank regions of homology to noncatalytic domains of the SRC oncogene product, SH2 and SH3.[supplied by OMIM]